Loading stock data…
CBIO
$18.00+0.72 (+4.17%)
After Hours$17.64-0.36 (-2.00%)· Last close Jun 9
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Crescent Biopharma, Inc. in the Healthcare sector is trading at $18.03 with a market capitalization of $496M. Wall Street consensus targets $31.67 (6 analysts), implying a +75.6% move over the next 12 months. The stock is currently 34% below its 52-week high of $27.41, remaining 27.3% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +75.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$18.00
Potential Downside
0%
Whystock Fair Value$18.00
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to trea...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$495.80M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-88.16%
Volume
Today's trading volume
126,104
Recent News
Crescent Biopharma: Q4 Earnings Snapshot
WALTHAM, Mass. AP) — Crescent Biopharma, Inc. CBIO) on Thursday reported a loss of $92.4 million in its fourth quarter.
Huge Insider Buying in MGM and Salesforce
As the year winds down, insiders make huge buys in MGM Resorts and Salesforce. However, those were not the only notable instances of insider buying seen recently.
Crescent and Kelun-Biotech swap cancer asset rights in double deal
The partnership includes regional rights to Crescent’s bispecific antibody and Kelun’s ADC.
Praxis soars higher; Bristol Myers’ CAR-T therapy wins broader use
Praxis shares climbed another 40% on a pair of positive updates on two different drugs. Elsewhere, Bristol Myers’ Breyanzi was cleared for its fifth cancer indication and AstraZeneca expanded a rare disease deal.
Crescent Biopharma, Kelun-Biotech Biopharmaceutical Partner in Multimillion Dollar Deal to Develop Cancer Drugs
Crescent Biopharma (CBIO) and Japan's Sichuan Kelun-Biotech Biopharmaceutical said Thursday that the